// App-Quantinova.ai

: CHOICES: A RANDOMIZED PHASE II TRIAL FOR IMATINIB VS HYDROXYCHLOROQUINE PLUS IM FOR PATIENTS WITH CML IN MCYR WITH RESIDUAL DISEASE DETECTABLE BY Q-PCR

Researchers

Presenter

  • Gillian A. Horne

Principal Investigators

  • Arunima Mukhopadhyay

  • Anne-Louise Latif

  • Jon Stobo

  • Caroline Kelly

  • Judith Dixon-Hughes

  • Lynn McMahon

  • Pascale Cony-Makhoul

  • Jenny Byrne

  • G. Vignir Helgason

  • Richard E. Clark

  • Dragana Milojkovic

  • Letizia Foroni

  • Franck E. Nicolini

  • Mhairi Copland

  • Tessa L. Holyoake

Medical Centers

  • Paul O?Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom

  • Hematology Department,CH Annecy Genevois,Annecy,Francia

  • Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom

  • Royal Liverpool University Hospital, Liverpool, United Kingdom

  • NCRI and Imperial College London, London, United Kingdom

  • Pathology Department, Centre Leon Berard, Lyon, France

Locations

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Hydroxychloroquine

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Multiple Arm

  • Multinational

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved